期刊文献+
共找到269篇文章
< 1 2 14 >
每页显示 20 50 100
Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies:Who and Why?
1
作者 Matteo Tonnini Clara Solera Horna Luca Ielasi 《World Journal of Gastroenterology》 SCIE CAS 2024年第5期509-511,共3页
The risk of reactivation in patients with chronic or past/resolved hepatitis B virus(HBV)infection receiving chemotherapy or immunosuppressive drugs is a wellknown possibility.The indication of antiviral prophylaxis w... The risk of reactivation in patients with chronic or past/resolved hepatitis B virus(HBV)infection receiving chemotherapy or immunosuppressive drugs is a wellknown possibility.The indication of antiviral prophylaxis with nucleo(t)side analogue is given according to the risk of HBV reactivation of the prescribed therapy.Though the advent of new drugs is occurring in all the field of medicine,in the setting of hematologic malignancies the last few years have been characterized by several drug classes and innovative cellular treatment.As novel therapies,there are few data about the rate of HBV reactivation and the decision of starting or not an antiviral prophylaxis could be challenging.Moreover,patients are often treated with a combination of different drugs,so evaluating the actual role of these new therapies in increasing the risk of HBV reactivation is difficult.First results are now available,but further studies are still needed.Patients with chronic HBV infection[hepatitis B surface antigen(HBsAg)positive]are reasonably all treated.Past/resolved HBV patients(HBsAg negative)are the actual area of uncertainty where it could be difficult choosing between prophylaxis and pre-emptive strategy. 展开更多
关键词 Hepatitis B reactivation Hepatitis B virus Antiviral prophylaxis hematologic malignancies Chimeric antigens receptor-T cell therapy Immune checkpoint inhibitors
下载PDF
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era 被引量:10
2
作者 Joyce Wing Yan Mak Alvin Wing Hin Law +3 位作者 Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law 《World Journal of Gastroenterology》 SCIE CAS 2023年第33期4942-4961,共20页
Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing... Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation.Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver.The expression of these silent genomes is controlled by the immune system.Suppression or ablation of immune cells,most importantly B cells,may lead to reactivation of seemingly resolved HBV infection.Thus,all patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBsAg)and antibody to hepatitis B core antigen.Patients found to be positive for HBsAg should be given prophylactic antiviral therapy.For patients with resolved HBV infection,there are two approaches.The first is pre-emptive therapy guided by serial HBV DNA monitoring,and treatment with antiviral therapy as soon as HBV DNA becomes detectable.The second approach is prophy-lactic antiviral therapy,particularly for patients receiving high-risk therapy,especially anti-CD20 monoclonal antibody or hematopoietic stem cell transplantation.Entecavir and tenofovir are the preferred antiviral choices.Many new effective therapies for hematological malignancies have been introduced in the past decade,for example,chimeric antigen receptor(CAR)-T cell therapy,novel monoclonal antibodies,bispecific antibody drug conjugates,and small molecule inhibitors,which may be associated with HBV reactivation.Although there is limited evidence to guide the optimal preventive measures,we recommend antivi-ral prophylaxis in HBsAg-positive patients receiving novel treatments,including Bruton’s tyrosine kinase inhibitors,B-cell lymphoma 2 inhibitors,and CAR-T cell therapy.Further studies are needed to determine the risk of HBV reactivation with these agents and the best prophylactic strategy. 展开更多
关键词 Hepatitis B hematologic neoplasms Chimeric antigen receptor-T cell therapy Monoclonal antibodies Bruton’s tyrosine kinase inhibitors Antiviral agents
下载PDF
Efficacy and Safety Assessment of Antifungal Sequential Therapy from Micafungin to Liposomal Amphotericin B for Antibiotics-Refractory Febrile Neutropenia in Patients with Hematologic Malignancies
3
作者 Kazunori Nakase Koji Oka +3 位作者 Keiki Kawakami Tetsuya Tsukada Shigehisa Tamaki Atsushi Fujieda 《Advances in Microbiology》 2023年第6期315-322,共8页
Invasive fungal infections are a major challenging problem in the management of febrile neutropenia (FN) in patients with hematologic malignancies. Liposomal amphotericin B (L-AmB) or micafungin (MCFG) has been widely... Invasive fungal infections are a major challenging problem in the management of febrile neutropenia (FN) in patients with hematologic malignancies. Liposomal amphotericin B (L-AmB) or micafungin (MCFG) has been widely used as a first-line empirical antifungal therapy for suspected fungal infection in such patients. However, there are several issues in patients receiving these agents: drug related toxicities for L-AmB and breakthrough fungal infections for MCFG. In order to make the best use of these 2 agents, we conducted a prospective study of sequential therapy from MCFG to L-AmB, and evaluated the efficacy and safety of this strategy in FN patients with hematologic malignancies. A total of 18 patients were enrolled, and 11 patients who fulfilled the protocol defined criteria were evaluated. Underlying diseases consisted of acute leukemia (n = 9), non-Hodgkin lymphoma (n = 1), and myelodysplastic syndrome (n = 1). Treatment success was achieved in 8 patients (72.7%). Drug-related adverse events occurred in 8 patients (72.7%). All of those adverse events except one case were below grade 2. Three patients required discontinuation of L-AmB. Although our empirical antifungal sequential therapy seems to be encouraging for antibiotics-refractory FN in patients with hematologic malignancies, further investigation in large-scale studies is warranted. 展开更多
关键词 Empirical Antifungal therapy MICAFUNGIN Liposomal Amphotericin B Febrile Neutropenia hematologic Malignancy
下载PDF
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy 被引量:15
4
作者 Man Fai Law Rita Ho +8 位作者 Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam 《World Journal of Gastroenterology》 SCIE CAS 2016年第28期6484-6500,共17页
Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabc... Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. 展开更多
关键词 Hepatitis B virus reactivation hematological malignancies RITUXIMAB Hematopoietic stem cell transplant Prophylactic antiviral therapy
下载PDF
CAR T Cell Therapy for Hematological Malignancies 被引量:3
5
作者 Xin YANG Gao-xiang WANG Jian-feng ZHOU 《Current Medical Science》 SCIE CAS 2019年第6期874-882,共9页
As a rapidly progressing field in oncology,the adoptive transfer of T cells that have been genetically modified with chimeric antigen receptors(CARs)has shown striking efficacy in the management of hematological malig... As a rapidly progressing field in oncology,the adoptive transfer of T cells that have been genetically modified with chimeric antigen receptors(CARs)has shown striking efficacy in the management of hematological malignancies and has been reported in a number of clinical trials.of note,CAR T cell therapy has shown extraordinary potential,especially in relapsed/refractory patients.However,there are still challenges regarding the further development of this strategy,spanning from engineering and manufacturing issues,to limited applications,to accompanying toxicities.In this review,we will summarize the general knowledge of this novel method,including receptor composition,applications,adverse events and challenges.Additionally,we will propose several comprehensive recommendations. 展开更多
关键词 immune therapy chimeric antigen receptor T cells hematological malignancies
下载PDF
Hepatitis B in patients with hematological diseases: An update 被引量:5
6
作者 Chiara Coluccio Paola Begini +5 位作者 Alfredo Marzano Adriano Pellicelli Barbara Imperatrice Giulia Anania Gianfranco Delle Fave Massimo Marignani 《World Journal of Hepatology》 CAS 2017年第25期1043-1053,共11页
Hepatitis B virus(HBV) reactivation(HBVr) in patients undergoing immunosuppressive therapy is still a hot topic worldwide. Its prevention and management still represents a challenge for specialists dealing with immuno... Hepatitis B virus(HBV) reactivation(HBVr) in patients undergoing immunosuppressive therapy is still a hot topic worldwide. Its prevention and management still represents a challenge for specialists dealing with immunosuppressed patients. Aim of this paper is to provide a critical review of the relevant information emerged in the recent literature regarding HBV reactivation following immunosuppressive treatments for oncohematological tumors. A computerized literature search in MEDLINE was performed using appropriate terms arrangement, including English-written literature only or additional relevant articles. Articles published only in abstract form and case reports not giving considerable news were excluded. Clinical manifestation of HBVr can be manifold, ranging from asymptomatic self-limiting anicteric hepatitis to life-threatening fulminant liver failure. In clusters of patients adverse outcomes are potentially predictable. Clinicians should be aware of the inherent risk of HBVr among the different virological categories(active carriers, occult HBV carriers and inactive carriers, the most intriguing category), and classes of immunosuppressive drugs. We recommend that patients undergoing immunosuppressive treatments for hematological malignancies should undergo HBV screening. In case of serological sign(s) of current or past infection with the virus, appropriate therapeutic or preventive strategies are suggested, according to both virological categories, risk of HBVr by immunosuppressive drugsand liver status. Either antiviral drug management and surveillance and pre-emptive approach are examined, commenting the current international recommendations about this debated issue. 展开更多
关键词 REACTIVATION Lymphoma hematologY Immunosuppressive therapy PROPHYLAXIS Hepatitis B virus Chemotherapy Occult/active/inactive carrier ENTECAVIR LAMIVUDINE
下载PDF
IRAK4在血液系统恶性肿瘤中的作用及其机制研究进展
7
作者 商颖 李莉娟 张连生 《解放军医学杂志》 CAS CSCD 北大核心 2024年第9期1094-1098,共5页
白细胞介素-1受体相关激酶4(IRAK4)在TLRs/IL-1R信号通路中发挥着关键的信号转导及调控作用,协调涉及免疫系统启动、细胞因子产生和细胞增殖与分化的多种炎症途径,与血液系统恶性肿瘤的发病机制和进展有关,包括骨髓增生异常综合征、急... 白细胞介素-1受体相关激酶4(IRAK4)在TLRs/IL-1R信号通路中发挥着关键的信号转导及调控作用,协调涉及免疫系统启动、细胞因子产生和细胞增殖与分化的多种炎症途径,与血液系统恶性肿瘤的发病机制和进展有关,包括骨髓增生异常综合征、急性髓系白血病、慢性淋巴细胞白血病和淋巴瘤等疾病。因此,IRAK4可能为血液系统恶性肿瘤的有效治疗靶点。本文就IRAK4的结构和功能及其在血液系统恶性肿瘤中的作用机制和治疗等方面的研究进展进行综述,旨在为揭示相关疾病的发生机制和靶向治疗研究提供参考。 展开更多
关键词 白细胞介素-1受体相关激酶4 血液系统恶性肿瘤 发病机制 靶向治疗
下载PDF
血液肿瘤精准诊治 被引量:1
8
作者 张曦 《陆军军医大学学报》 CAS CSCD 北大核心 2024年第4期299-310,共12页
目的 随着对血液肿瘤发病机制的深入研究,血液肿瘤的精准诊断和分层治疗逐年优化提升。近年来在人工智能的推动下,血液肿瘤诊断由人工化、经验化不断向智能化、信息化升级,在未来有望实现高效、高准确率的智能诊断;同时,小分子药物、抗... 目的 随着对血液肿瘤发病机制的深入研究,血液肿瘤的精准诊断和分层治疗逐年优化提升。近年来在人工智能的推动下,血液肿瘤诊断由人工化、经验化不断向智能化、信息化升级,在未来有望实现高效、高准确率的智能诊断;同时,小分子药物、抗体类药物、免疫细胞治疗及造血干细胞移植新疗法在不断完善,新药不断涌现,为血液肿瘤的治疗提供了更多选择。本文从血液肿瘤的精准/智能诊断、药物治疗和细胞治疗等3个方面探讨血液肿瘤的精准诊断与治疗。 展开更多
关键词 血液肿瘤 精准诊断 靶向治疗
下载PDF
静脉通路安全管理在血液系统恶性肿瘤患者围化疗期的效果评价
9
作者 王石娟 朱茂冰 +5 位作者 卢昌媛 黄思霖 石夕巧 李敏 张丽凤 劳永聪 《中国医药科学》 2024年第5期165-168,共4页
目的探讨静脉通路安全管理在血液恶性肿瘤患者围化疗期管理中的应用效果。方法选取广西医科大学附属肿瘤医院淋巴血液及儿童肿瘤内科252例血液系统恶性肿瘤围化疗期患者为研究对象,2021年5月至2022年7月126例为研究组(常规管理+静脉通... 目的探讨静脉通路安全管理在血液恶性肿瘤患者围化疗期管理中的应用效果。方法选取广西医科大学附属肿瘤医院淋巴血液及儿童肿瘤内科252例血液系统恶性肿瘤围化疗期患者为研究对象,2021年5月至2022年7月126例为研究组(常规管理+静脉通路安全管理),2019年5月至2020年7月为对照组(常规管理)。比较两组患者的导管感染、药物渗出/外渗、静脉炎发生情况和患者满意度;比较两组护理人员在患者输液工具选择、导管固定、敷料维护的正确情况。结果研究组围化疗期导管感染、药物渗出/外渗、静脉炎总发生率明显低于对照组;研究组围化疗期患者的输液工具选择正确率、导管固定正确率、敷料维护正确率高于对照组;研究组护理满意度高于对照组,差异均具有统计学意义(P<0.05)。结论血液恶性肿瘤患者围化疗期进行静脉通路安全管理,可降低静脉血管通路并发症的发生,同时可提高患者对护理工作的满意度,有一定的临床应用价值。 展开更多
关键词 静脉通路 静脉治疗 血液系统恶性肿瘤 化疗
下载PDF
1例儿童血液恶性肿瘤肺毛霉菌病的抗感染治疗
10
作者 吕佳窈 杨敏 《实用药物与临床》 CAS 2024年第5期391-395,共5页
1例诊断为血液恶性肿瘤肺毛霉菌病的7岁儿童,给予两性霉素B进行抗感染治疗,用药期间血肌酐进行性升高,考虑为两性霉素B所致的药物不良反应,下调两性霉素B剂量后,胸部CT示左肺团块影较前呈增大趋势,考虑药物剂量不足、疗效欠佳,但再次上... 1例诊断为血液恶性肿瘤肺毛霉菌病的7岁儿童,给予两性霉素B进行抗感染治疗,用药期间血肌酐进行性升高,考虑为两性霉素B所致的药物不良反应,下调两性霉素B剂量后,胸部CT示左肺团块影较前呈增大趋势,考虑药物剂量不足、疗效欠佳,但再次上调剂量肾损害风险增加。经综合评估后,停用两性霉素B,改为泊沙康唑混悬液口服序贯抗真菌治疗,且出院后持续服用,定期行化疗方案,并随访左肺结节变化情况。患儿出院5个月后,胸部CT示左肺团块影基本吸收,治疗有效。结合本例患儿的抗感染治疗方案,本文对儿童毛霉菌病的治疗药物选择、用法用量及不良反应等进行了分析讨论。儿童毛霉菌病的抗感染治疗可能需要更高的个性化剂量及严密的监测才能保证安全性及有效性。 展开更多
关键词 儿童 血液恶性肿瘤 毛霉菌病 抗感染治疗
下载PDF
实体瘤治疗相关血液肿瘤的研究进展
11
作者 孙碧文 郑鸿 +1 位作者 王亚非(综述) 田晨(审校) 《中国肿瘤临床》 CAS CSCD 北大核心 2024年第10期534-537,共4页
近年来实体瘤治疗相关血液肿瘤的发病率呈增长趋势,相比原发血液肿瘤,治疗相关血液肿瘤的预后更差,是实体瘤治疗后最严重的并发症之一。潜能未定的克隆性造血(clonal haematopoiesis of indeterminate potential,CHIP)已被认为是治疗相... 近年来实体瘤治疗相关血液肿瘤的发病率呈增长趋势,相比原发血液肿瘤,治疗相关血液肿瘤的预后更差,是实体瘤治疗后最严重的并发症之一。潜能未定的克隆性造血(clonal haematopoiesis of indeterminate potential,CHIP)已被认为是治疗相关髓系肿瘤(therapy-related myeloid neoplasm,t-MN)发病机制中的相关因素,通过促进驱动基因突变导致t-MN风险增加。治疗相关性血液肿瘤的发病主要与烷化剂、拓扑异构酶抑制剂、铂类化合物、PARP抑制剂及放射治疗有关。目前,同种异体造血干细胞移植仍然是治疗相关血液肿瘤的最佳治疗方案。本综述旨在分析T-MN的流行病学、发病机制、相关药物、预后及治疗等方面的进展。 展开更多
关键词 实体瘤 治疗相关血液肿瘤 治疗相关髓系肿瘤
下载PDF
TRBC1作为潜在靶点治疗T细胞来源肿瘤的研究进展
12
作者 周萌 李慧 《现代肿瘤医学》 CAS 2024年第6期1163-1166,共4页
T细胞来源肿瘤具有侵袭性、易耐药且预后不良的特点,常规治疗后复发率高,目前对于其的治疗不存在特效药。若能改进早期诊断和治疗手段,将有效改善患者的预后。细胞免疫治疗对B细胞来源的血液系统肿瘤获得较高的治愈率。却因为缺乏合适... T细胞来源肿瘤具有侵袭性、易耐药且预后不良的特点,常规治疗后复发率高,目前对于其的治疗不存在特效药。若能改进早期诊断和治疗手段,将有效改善患者的预后。细胞免疫治疗对B细胞来源的血液系统肿瘤获得较高的治愈率。却因为缺乏合适的靶点对治疗T细胞来源血液系统肿瘤的免疫治疗效果不佳。最新发现的T细胞受体β链恒定结构域1(TRBC1)作为一个潜在的治疗靶点,给T细胞来源肿瘤的诊断和治疗带来希望。本文将对TRBC1在当前的疾病诊断和细胞免疫治疗中研究进展进行综述。 展开更多
关键词 T细胞抗原受体 T细胞受体β链恒定结构域1 血液肿瘤诊断 CAR-T细胞治疗 T细胞活化信号转导
下载PDF
尼洛替尼治疗慢性粒细胞白血病临床观察及药品不良反应与UGT UGT1A1基因多态性相关性分析
13
作者 曾丽华 闰国伟 +3 位作者 余碧珍 许静霞 毕景楠 冀林华 《中国药业》 CAS 2024年第S02期26-28,共3页
目的探讨尼洛替尼治疗慢性粒细胞白血病(CML)的临床疗效,以及药品不良反应与UGT1A1基因多态性的相关性。方法选取医院2020年9月至2023年8月收治的13例伊马替尼耐药或不耐受CML患者为研究对象,均接受尼洛替尼治疗,观察临床疗效及药品不... 目的探讨尼洛替尼治疗慢性粒细胞白血病(CML)的临床疗效,以及药品不良反应与UGT1A1基因多态性的相关性。方法选取医院2020年9月至2023年8月收治的13例伊马替尼耐药或不耐受CML患者为研究对象,均接受尼洛替尼治疗,观察临床疗效及药品不良反应与UGT1A1基因多态性的相关性。结果与治疗前比较,患者治疗后的血液学、分子生物学的整体疗效显著(P<0.05);且治疗后的毒性反应发生率更低(P<0.05)。患者存在4种UGT1A1基因表型,分别为UGT1A1*6 GG、UGT1A1*6 GA、UGT1A1*286/6 TA、UGT1A1*286/7 TA,UGT1A1*28基因表型为6/7 TA的患者更易出现严重的不良反应。结论在伊马替尼耐药或不耐受CML治疗过程中应用尼洛替尼,能改善患者血液学、分子生物学疗效,大幅降低毒性反应。尼洛替尼不良反应与UGT1A1基因多态性相关,对UGT1A1型28基型表型患者应更密切关注其不良反应。。 展开更多
关键词 伊马替尼耐药 伊马替尼不耐受 慢性粒细胞白血病 尼洛替尼 血液学治疗效果 分子生物学治疗 UGT1A1基因多态性
下载PDF
理性情绪疗法联合正念冥想对恶性血液病病人焦虑情绪、主观幸福感的影响
14
作者 虞婷 张黎晴 储霜 《循证护理》 2024年第12期2268-2271,共4页
目的:探讨理性情绪疗法联合正念冥想对恶性血液病病人焦虑情绪变化及主观幸福感的影响。方法:于2020年8月—2022年7月选取我院收治的恶性血液疾病病人122例为研究对象,按双色球法随机分为对照组61例和干预组61例,对照组采用常规护理,干... 目的:探讨理性情绪疗法联合正念冥想对恶性血液病病人焦虑情绪变化及主观幸福感的影响。方法:于2020年8月—2022年7月选取我院收治的恶性血液疾病病人122例为研究对象,按双色球法随机分为对照组61例和干预组61例,对照组采用常规护理,干预组在其基础上进行理性情绪疗法联合正念冥想;于干预前及干预后1、2、3、4周采用中文版状态-特质焦虑量表中的状态焦虑(SAI)子量表对研究对象的焦虑情绪变化进行评价,干预前及干预4周后采用总体幸福感量表(GWB)对研究对象的主观幸福感进行评价。结果:干预组SAI评分随干预时间的增加逐渐降低,且干预后1、2、3、4周均低于同期对照组;干预4周后GWB总分及各维度得分均高于对照组,差异均有统计学意义(P<0.05)。结论:理性情绪疗法联合正念冥想训练可有效改善恶性血液疾病病人焦虑情绪,提高主观幸福感。 展开更多
关键词 理性情绪疗法 正念冥想 恶性血液病 焦虑 主观幸福感 护理
下载PDF
An exciting time to launch the World Journal of Hematology
15
作者 Xiaoyan Jiang 《World Journal of Hematology》 2012年第1期1-4,共4页
This first issue of the World Journal of Hematology(WJH) marks the birth of a new member of the World Series Journal family and comes at one of the most exciting times in stem cell biology and translational medicine. ... This first issue of the World Journal of Hematology(WJH) marks the birth of a new member of the World Series Journal family and comes at one of the most exciting times in stem cell biology and translational medicine. The pace of discovery in the field of hematology has accelerated signeificantly in recent years, due to important scientific discoveries and new technologies for purification of hematopoietic stem cells and identification of specific stem cell biomarkers; whole genome sequencing using next-generation sequencing technology; and development of molecularly-targeted therapies, leading to the translation of highly promising science into advanced diagnosis and proven targeted therapies for hematopoietic disorders. The WJH is an open-access, peer-reviewed journal, which is officially published on June 6, 2012. The WJH Editorial Board consists of 102 experts in hematology from 26 countries. There is clearly a niche for this new journal, which provides access to all articles without boundaries to all internet users throughout the world. The WJH aims to provide rapid access to high impact publications in fundamental and clinical hematology, with multidisciplinary coverage, through an established system that is targeted at dissemination to the scientific community via online openaccess. 展开更多
关键词 hematologY Biomedical sciences Translational medicine Stem cell biology Next-generation sequencing Molecular targeted therapies TYROSINE kinase inhibitors Chronic myeloid LEUKEMIA Acute PROMYELOCYTIC LEUKEMIA PEER-REVIEWED Open-access JOURNAL
下载PDF
CRRT治疗病人血液透析滤过管采血行血液学检测的研究进展
16
作者 易金燕 杨丽 +3 位作者 钟博华 易紫辉 许伟 林海成 《护理研究》 北大核心 2023年第16期2928-2933,共6页
对国内外行连续肾脏替代疗法治疗病人血液透析滤过管采血行血液学检测的研究文献进行综述,以期为改善护理工作人员的操作流程提供参考依据,为危重病人的采血途径提供新思路与临床借鉴。
关键词 连续肾脏替代疗法 采血 血液学 检测 综述
下载PDF
2023年CAR-T细胞在血液恶性肿瘤治疗的研究进展
17
作者 李珊 梁书洁 +1 位作者 赖沛龙 杜欣 《循证医学》 2023年第6期328-331,370,共5页
血液系统恶性肿瘤是最常见的癌症之一,目前,血液系统恶性肿瘤的主要治疗方法是干细胞移植、化疗和放疗,虽然有良好的治疗效果,但容易复发。嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法作为一种革命性的细胞免疫治疗手段,为... 血液系统恶性肿瘤是最常见的癌症之一,目前,血液系统恶性肿瘤的主要治疗方法是干细胞移植、化疗和放疗,虽然有良好的治疗效果,但容易复发。嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法作为一种革命性的细胞免疫治疗手段,为复发难治性(relapsed or refractory,R/R)血液恶性肿瘤患者带来了新的希望。 展开更多
关键词 血液恶性肿瘤 嵌合抗原受体T细胞疗法 细胞免疫疗法
下载PDF
血液肿瘤患者血管通路装置选择的研究进展 被引量:5
18
作者 季奕君 赵林芳 +1 位作者 陈思洁 钱颖 《护理学杂志》 CSCD 北大核心 2023年第11期109-112,共4页
基于血液肿瘤患者使用血管通路需求大、导管相关并发症发生率高的特点,对有关血液肿瘤患者血管通路装置的置管时机、置管部位、导管类型选择的研究文献进行综述,旨在为我国血液肿瘤患者更合理地应用血管通路装置提供参考。
关键词 血液肿瘤 血管通路装置 中心静脉导管 静脉治疗 并发症 综述文献
下载PDF
中医药治疗急性淋巴细胞白血病的临床及机制研究进展 被引量:3
19
作者 程奕暄 牛群 +3 位作者 孙书章 侯宛昕 李和根 肖宁 《中国医药导报》 CAS 2023年第15期49-52,共4页
急性淋巴细胞白血病(ALL)是一种发生在人体血液系统的恶性肿瘤,在各个年龄段均可发生,发病后常伴有发热、出血、贫血、器官损伤等症状。近年来中医药治疗ALL取得了一定进展,本文将从临床辨证分型治疗与分子生物学机制角度对中医药治疗AL... 急性淋巴细胞白血病(ALL)是一种发生在人体血液系统的恶性肿瘤,在各个年龄段均可发生,发病后常伴有发热、出血、贫血、器官损伤等症状。近年来中医药治疗ALL取得了一定进展,本文将从临床辨证分型治疗与分子生物学机制角度对中医药治疗ALL的现状进行系统总结,揭示中医药治疗ALL在减少化疗不良反应、降低耐药复发、诱导细胞凋亡与自噬、抑制细胞增殖与肿瘤侵袭转移、逆转多药耐药及减毒增效等方面的潜在优势,明确中医药疗法可有效延长ALL患者生命、减少复发的独特功效,旨在为临床治疗ALL提供新启示和新思路。 展开更多
关键词 血液肿瘤 急性淋巴细胞白血病 中医药疗法 减毒增效 分子机制
下载PDF
Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort 被引量:9
20
作者 CHENG Shu ZHOU Jian-feng ZOU Ping HUANG Xiao-jun JIN Jie SHEN Zhi-xiang 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第22期3670-3675,共6页
Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of p... Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies. Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China. Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia 〉10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity. Conclusion Itraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. 展开更多
关键词 itraconazole hematologic malignancy febrile neutropenia empirical therapy
原文传递
上一页 1 2 14 下一页 到第
使用帮助 返回顶部